The Scientific Program - Parkinson's Disease and Movement Disorders (PDMD)
|
Saturday, April 06, 2019 |
|
Hall A- CAJAL |
|
|
07:00-08:00 |
E-Poster Presentations Michael Ugryumov, Denis Pokhabov PD FREE COMMUNICATIONS |
||
|
08:00-10:30 |
SESSION 22 | ORTHOSTATIC HYPOTENSION IN PD: IMAGING |
||
|
Chairpersons: |
|
||
|
08:00-08:50 |
DAT imaging with SPECT or PET in parkinsonism: which one to choose? |
||
|
08:00-08:10 |
Host: Javier Arbizu, Spain |
||
|
08:10-08:25 |
Pro SPECT: Pierre Payoux, France |
||
|
08:25-08:40 |
Pro PET: Andrea Varrone, Sweden |
||
|
08:40-08:50 |
Discussion and rebuttals |
||
|
08:50-09:40
09:00-09:15 09:15-09:30 09:30-09:40 |
Wearable technology devices will replace clinical PD motor assessments. Capsule: The current standard of PD management relies on patient histories and neurological examinations. However the infrequent nature of medical visits limits the ability to optimize care. With wearable technologies, neurologists can now collect longer durations of patient information and utilize these continuous objective measures to tailor management and do so with greater precision.
Host: Rajesh Pahwa, USA Pro: Fatta Nahab, USA Con: Pablo Martinez-Martin, Spain Discussion and rebuttals |
||
|
|
|
||
|
09:40-10:30 |
Neurogenic orthostatic hypotension is a major cause of disability in PD. |
||
|
|
Capsule: |
||
|
09:40-09:50 |
Host: Tatyana Slobodin, Ukraine |
||
|
09:50-10:05 |
Pro: David Goldstein, USA |
||
|
10:05-10:20 |
Con: |
||
|
10:20-10:30 |
Discussion and rebuttals |
||
|
10:30-10:45 |
Coffee Break |
||
|
10:45-12:25 |
SESSION 23 | PD: PSYCHOSIS AND MOTOR FLUCTUATIONS |
||
|
Chairpersons: |
Victoria Gryb, Ukraine, & Diego Santos Garcia, Spain |
||
|
10:45-11:35 |
Treating PD psychosis early improves long-term outcomes. |
||
|
|
Capsule: Psychosis is commonly observed as a consequence of PD therapy. However the type of perceptual disturbance or thought content varies. The co-occurrence of depression, psychosis and dementia in patients with PD may indicate a more widespread pathological process affecting many neurotransmitter systems. Would early treatment of psychosis improve long-term outcomes? |
||
|
10:45-10:55 |
Host: Nestor Galvez, USA |
||
|
10:55-11:10 |
Pro: Daniel Kremens, USA |
||
|
11:10-11:25 |
Con: Jaime Kulisevsky, Spain |
||
|
11:25-11:35 |
Discussion and rebuttals |
||
|
|
|
||
|
11:35-12:25 |
Gastrointestinal dysmotility is the major cause of motor fluctuations in PD. |
||
|
|
Capsule: Erratic gastric emptying is certainly one cause for fluctuations in advanced disease. However, dopaminergic neurons depletion and limited levodopa storage are the classical causes of fluctuations. Then should we treat brain or should we treat stomach and gut in PD? |
||
|
11:35-11:45 |
Host: Stuart Isaacson, USA |
||
|
11:45-12:00 |
Pro: Bogdan Popescu, Romania |
||
|
12:00-12:15 |
Con: Esther Cubo, Spain |
||
|
12:15-12:25 |
Discussion and rebuttals |
||
|
12:25-13:25 |
Lunch Break |
||
|
12:25-13:25 |
Meet the Expert - PDMD (Rio Hortega) Emerging perspectives regarding the use of on-demand therapies to treat OFF episodes in PD. Per Odin, Sweden Mark Lew, USA Stuart Isaacson, USA |
||
|
12:25-13:25 |
Meet the Expert - PDMD (Lafora) Neurogenic Orthostatic Hypotension: I. Clinical Diagnosis of NOH; II. Distinguishing NOH from OFF Symptoms; III. Currrent Approach to NOH Treatment Dr. Fiona Gupta, Dr. Fatta Nahab MD, Dr. Laxman Bahroo, Dr, Stuart Isaacson |
||
|
13:25-15:05 |
SESSION 24 | DYSKINESIAS |
||
|
Chairpersons: |
Pablo Mir Rivera, Spain & Angela Deutschlaender, USA |
||
|
13:25-14:15 |
Medical treatment of dyskinesia is as effective as deep brain stimulation (DBS). |
||
|
|
Capsule: Dyskinesias affect a significant proportion of patients with PD, and is mostly observed after disease durations of several years. The presence of severe motor fluctuations and dyskinesias is one of the most important reasons for clinicians to recommend DBS. Can medical treatment achieve a reduction of dyskinesias which is comparable to DBS? |
||
|
13:25-13:35 |
Host: Fiona Gupta, USA |
||
|
13:35-13:50 |
Pro: Vladimira Vuletic, Croatia |
||
|
13:50-14:05 |
Con: Sharon Hassin-Baer, Israel |
||
|
14:05-14:15 |
Discussion and rebuttals |
||
|
|
|
||
|
14:15-15:05 |
Tardive dyskinesia (TD) remains a common consequence of conventional antipsychotics. |
||
|
|
Capsule: TD represents involuntary movements affecting face, trunk or extremities, usually occurring after treatment with antipsychotics. The prevalence of TD in patients treated with conventional antipsychotic drugs ranges between 20-50%, and atypical antipsychotic drugs are thought to carry a lower risk of TD. These involuntary movements, may disappear after discontinuation of the incriminated drug. How do we do the long-term management of the psychiatric patient that developed TD? |
||
|
14:15-14:25 |
Host: Pedro Garcia Ruiz Espiga, Spain |
||
|
14:25-14:40 |
Pro: Laxman Bahroo, USA |
||
|
14:40-14:55 |
Con: Cristian Falup-Pecurariu, Romania |
||
|
14:55-15:05 |
Discussion and rebuttals |
||
|
15:05-15:20 |
Coffee Break |
||
|
15:20-17:50 |
SESSION 25 | ADVANCED DOPAMINERGIC THERAPIES IN PD |
||
|
Chairpersons: |
Miquel Aguilar-Barberá, Spain |
||
|
15:20-16:10 |
Off time will disappear with longer acting levodopa (LD) formulations. |
||
|
|
Capsule: The so called "honeymoon" period of good response to LD in PD lasts after 5-7 years. The mechanisms responsible for the loss of smooth response are complex and include gastric emptying as well as pharmacokinetic and pharmacodynamic factors. Could a better LD formulation solve the problem? |
||
|
15:20-15:30 |
Host: Georgia Xiromerisiou, Greece |
||
|
15:30-15:45 |
Pro: Diego Santos Garcia, Spain |
||
|
15:45-16:00 |
Con: Jaroslaw Slawek, Poland |
||
|
16:00-16:10 |
Discussion and rebuttals |
||
|
|
|
||
|
16:10-17:00 |
Subcutaneous apomorphine infusion should be used before other advanced therapies. |
||
|
|
Capsule: Subcutaneous apomorphine infusion and advanced therapies of motor symptoms of PD intrajejunal levodopa infusions and DBS, each with distinct side effects. The individual PD symptoms profile should be assessed in order to choose an optimal treatment option. Should we use apomorphine infusions prior to recommending DBS surgery or intrajejunal levodopa infusions? |
||
|
16:10-16:20 |
Host: Stuart Isaacson, USA |
||
|
16:20-16:35 |
Pro: Mark Lew, USA |
||
|
16:35-16:50 |
Con: Per Odin, Sweden |
||
|
16:50-17:00 |
Discussion and rebuttals |
||
|
|
|
||
|
17:00-17:50 |
Development of non-dopaminergic therapies is a greater unmet need than dopaminergic treatments. |
||
|
|
Capsule: PD patients suffer motor and non-motor symptoms. Most motor symptoms are dopamine-responsive. But some motor symptoms, such as tremor, as well as non-motor symptoms, may not respond and even worsen with dopaminergic medication. The question therefore arises whether development of non-dopaminergic therapies is a greater unmet need than dopaminergic treatments. |
||
|
17:00-17:10 |
Host: Marios Politis, UK |
||
|
17:10-17:25 |
Pro: Abdelhamid Benazzouz, France |
||
|
17:25-17:40 |
Con: Ilana Schlesinger, Israel |
||
|
17:40-17:50 |
Discussion and rebuttals |
||
|
|
|
||
|
17:50-19:00 |
Should depression be a consideration when choosing an anti HD therapy? |
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
18:00-19:00 |
Meet the Expert - PDMD (Lorente de Nó) OFF Episodes in PD: GI Dysmotility and Emerging Non-Oral, On-Demand Therapies
Laxman Bahroo, Dr. Stuart Isaacson, Dr. Fiona Gupta |
||
|
END OF SATURDAY HALL A- CAJAL |
|||
|
Sunday April 07, 2019 |
|
Hall A- CAJAL |
|
|
07:00-08:00 |
E-Poster Presentations |
||
|
08:00-10:00 |
SESSION 40 | PARKINSONS DISEASE (PD): COPPADIS MEETING |
||
|
Chairpersons: |
Juan Carlos Martínez Castrillo, Spain & Jaime Kulisevsky, Spain |
||
|
|
Capsule: Well-designed, prospective studies for identifying PD progression biomarkers are necessary. COPPADIS-2015 (Cohort of Patient´s with Parkinson's Disease in Spain, 2015) is an observational, descriptive, 5-year follow-up, nationwide study with more than 1,000 subjects participating that try to provide important knowledge about PD progression. Here, we show some interesting data about this ongoing project. |
||
|
08:00-08:30 |
COPPADIS-2015. Justification, objective and general aspects of the project: Diego Santos Garcia, Spain |
||
|
08:30-08:50 |
Non-motor symptoms in PD: frequency, types and correlated factors. Lluis Planellas Gine, Spain |
||
|
08:50-09:10 |
Depression (BDI-II) in PD: prevalence, types, and variables. Miquel Aguilar Barberá, Spain |
||
|
09:10-09:30 |
Impulse control disorders and compulsive behaviours in PD. Silvia Jesús Maestre, Spain |
||
|
09:30-09:50 |
Factors affecting quality of life in patients with Parkinson´s disease: motor vs non-motor symptoms. Pablo Martínez-Martín, Spain |
||
|
09:50-10:00 |
Conclusion and future directions: Diego Santos Garcia, Spain, Juan Carlos Martínez Castrillo, Spain & Jaime Kulisevsky, Spain |
||
|
|
|
||
|
10:00-10:15 |
Coffee Break |
||
|
10:15-11:05 |
SESSION 41 | PARKINSON'S DISEASE |
||
|
Chairpersons: |
|
||
|
10:15-11:05 |
Is vascular parkinsonism (VaP) is a useful clinical entity? |
||
|
|
Capusle: The diagnosis of VaP is based on convergence of clinical parkinsonism with variable pyramidal and ataxic motor and non-motor signs, such as cognitive changes or bladder incontinence, that are corroborated by anatomic or imaging findings of cerebrovascular disease. Some experts disagree. |
||
|
10:15-10:25 |
Host: Fatta Nahab, USA |
||
|
10:25-10:40 |
Yes: Ivan Rektor, Czech Republic |
||
|
10:40-10:55 |
No: Oleg Levin, Russia |
||
|
10:55-11:05 |
Discussion and rebuttals |
||
|
11:05-13:00 |
SESSION 42 | HUNTINGTON'S DISEASE AND ADVANCED PD |
||
|
Chairpersons: |
Xiana Rodríguez Osorio, Spain |
||
|
11:05-11:55 |
Huntington's disease |
||
|
|
|
||
|
11:55-13:00 |
Round table discussion: What is 'advanced PD' and how to select the best advanced treatment (apomorphine vs duodopa vs DBS)? |
||
|
|
Host: Stuart Isaacson, USA |
||
|
|
Participants: Pedro Garcia Ruiz Espiga, Spain, Sharon Hassin-Baer, Israel; Mónica M Kurtis, Spain, Juan Carlos Martinez Castrillo, Spain, Irena Rektorova, Czech Republic; Jaroslaw Slawek, Poland |
||
